Author

Haley Johnson

University of California, San FranciscoPrimary ORCID profile (0000-0003-1092-1842 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Haley JohnsoniD1 paper · Johns Hopkins University

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:proteomics· 1

Frequent Co-Authors

Amrik S. KangiD· 2 shared Arun P. WiitaiD· 2 shared Bonell Patiño-EscobariD· 2 shared Emilio Ramos· 2 shared Fernando Salangsang· 2 shared Paul J. Phojanakong· 2 shared Veronica SteriiD· 2 shared Adila IzgutdinaiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Amrik S. KangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies

Adila Izgutdina, Tasfia Rashid, William C. Temple, Sarah Aminov, Bonell Patiño-Escobar, Sujata B. Walunj, Huimin Geng, Hiroyuki Takamatsu, Daniel Gil-Alós, Amrik S. Kang, Emilio Ramos, Szu‐Ying Chen, Haley Johnson, Matthew A. Nix, Akul Naik, , Arun P. Wiita

This study shows that affinity-matured CD72-targeting nanobody CAR T-cells improve in vitro efficacy against CD72-low tumors but show limited in vivo benefit, while CD72 expression remains stable after CD19 resistance in B-cell malignancies.

Journal for ImmunoTherapy of Cancer · Dec 1, 2025Peer-reviewedImmunology

Structure-guided engineering of CCL27 enhances natural ligand CAR T-cells against CCR10 for multiple myeloma

Nikhil Chilakapati, Bonell Patiño-Escobar, Emily Y. Chen, Radhika Dalal, Jonathan de Montagnac, Haley Johnson, Amrik S. Kang, Naomi Akagi, Emilio Ramos, Paul J. Phojanakong, Fernando Salangsang, Yan Zeng, Ajai Chari, Alfred Chung, Anupama Deepa Kumar, , Arun P. Wiita

This paper engineers CCL27 mutants to enhance CAR T-cell efficacy against multiple myeloma by targeting CCR10, achieving results comparable to BCMA CAR-Ts.

bioRxiv · Aug 19, 2025 · PreprintCancer Biology